

# Application of insertion sequence on genotyping and antimicrobial resistance gene identification

張仁齊、劉淑瑛、邱政洵

E-mail: 345463@mail.dyu.edu.tw

## ABSTRACT

*Acinetobacter baumannii* is an opportunistic pathogen, usually causing nosocomial infections in immunocompromised and elderly patients. Current antibiotics commonly used against *A. baumannii* are imipenem. In recent years, the imipenem resistance of *A. baumannii* is dramatically increased, due to the presence of ISAbal at the upstream of a beta-lactamase gene, blaOXA-23 or blaOXA-51. ISAbal inserted into the upstream of resistance genes can not only enhance gene expression, but also form a transposon, and therefore allow the nondrug-resistant bacteria to become drug-resistant, and facilitate the spread of drug resistance genes. In this study, sixty-two clinical *A. baumannii* isolates were collected for genotyping during from 2009 to 2010 from two hospitals in northern Taiwan, including Chang Gung Memorial Hospital and St. Paul 's Hospital. First, 61 of 62 isolates were divided into 41 genotypes by pulse field gel electrophoresis (PFGE); 13 genotypes were classified by PCR typing. This typing was developed to alternatively group *A. baumannii* isolates among the diverse PFGE genotypes in this study. We used two individual sets of nested PCR primers, where one side of two individual primer sets was chose according to a known gene sequence, i.e. a specific insertion sequence ISAbal. However, the other side could be any unknown DNA sequence, which may be targeted by a semi-random primer with a 14-base random sequence at the 3' end of primer and a 26-base multi-cloning-sites sequence at the 5' end, where this 26-base sequence may be used as a primer for the second round of PCR. When combining PFGE and PCR genotypes together with multi-drug resistance gene patterns, we found a major group of type I isolates that containing multiple drug-resistant genes or transposon-related sequences, including ISAbal-blaOXA-51-like (Tn6080-like), ISAbal-blaOXA-23-ISAbal (Tn2006), and ISAbal-blaOXA-23 (Tn2008). In contrast, type II or XIII isolates were in a minority without any common drug-resistant gene detected. We also used the same PCR method to sequence an unknown resistance gene that was flanked by a specific insertion sequence ISAbal for *A. baumannii* or ISEcp1 for *Klesiella pneumoniae* and *Escherichia coli* isolates. The sizes of any PCR-amplified fragments selected for DNA sequencing and NCBI database annotation were larger than 550 bp long. Only five of twelve *A. baumannii* resistance genes detected beside ISAbal were in consistent with the previously verified resistance genes. However, when detecting the flanking sequence of ISEcp1 in five of each extended-spectrum beta-bactamases-containing *K. pneumoniae* and *E. coli* isolates, seven of them promisingly exhibited the same results with the known data. Our study may offer an information for *A.baumannii* genotyping and an alternative approach to search drug resistance genes, and the resulting data may contribute to clinical antibiotic treatment.

Keywords : ISAbal、PCR-typing、OXA、*Acinetobacter baumannii*、PCR-typing

## Table of Contents

封面內頁 簽名頁 中文摘要	iii 英文摘要
v 誌謝	vii 目錄
viii 圖目錄	x 表目錄
xi 1. 緒論 1.1 不動桿菌屬 ( <i>Acinetobacter</i> spp.)	1 1.2 鮑氏不動桿菌 1 1.3
抗生素的作用	3 1.4 細菌的抗藥性 5 1.5 <i>A. baumannii</i> 的抗藥機
轉	6 1.6 <i>A. baumannii</i> 之抗藥性影響 7 1.7 ISAbal 對 <i>A. baumannii</i> 的影響 8 1.8 研究動機
	9 2. 材料與方法 2.1 菌株來源與保存 10 2.2 PCR-based ISAbal typing
10 2.2.1 PCR 模板 DNA 製備	10 2.2.2 引子 (primer) 設計與條件設計 11 2.3 Pulsed field gel
electrophoresis (PFGE) 12 2.3.1 菌體培養	12 2.3.2 菌體包埋及菌體溶解 12
2.3.3 膠塊清洗	13 2.3.4 限制酵素消化切割 14 2.3.5 電泳操作流程
14 2.4 分析 ISAbal 上游基因	15 3. 實驗結果 3.1 PCR-based ISAbal typing 結果 16 3.2
Pulsed field gel electrophoresis (PFGE) 結果	16 3.3 尋找 ISAbal 上游基因結果 17 3.4 尋找 ISEcp1 下游基因結
果	17 4. 討論 4.1 PCR-based ISAbal typing 19 4.2 尋找 insertion sequence 上下游的抗藥基
因	20 5. 結論 24 參考文獻 44
附錄	50 圖目錄 圖1. PCR 引子設計

26 圖2. PFGE 測試 S1-S25	27 圖3. PFGE 測試 S26-S40 及 C1	28
圖4. PFGE 測試 C6-C15	29 圖5. PFGE 測試 C16-C29	30
圖6. PFGE 測試 C30-C35	31 圖7. PCR typing 分型結果	32 表
目錄 表1. <i>A. baumannii</i> 編號及來源	34 表2. 所使用序列分析之引子	35 表3. PCR Typing
脈衝式電泳染色體基因之分型	37 表5. ISAbal 上游基因定序結果	38 表6. ISEcp1 下游基因定序結果
39 表7. 抗藥基因與 PCR typing 之比較	40	

## REFERENCES

1. Andriamanantena, T.S., E. Ratsima, H.C. Rakotonirina, F. Randrianirina, L. Ramparany, J.-F. Carod, V. Richard, and A. Talarmin. 2010. Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar. *Ann Clin Microbiol Antimicrob.* 9:17.
2. Azim, A., M. Dwivedi, P.B. Rao, A.K. Baronia, R.K. Singh, K.N. Prasad, B. Poddar, A. Mishra, M. Gurjar, and T.N. Dhole. 2010. Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum beta-lactamase- and metallo-beta-lactamase-producing Gram-negative bacteria--an Indian experience. *J Med Microbiol.* 59:955-960.
3. Bouvet, P. J. M., and P. A. D. Grimont. 1986. Taxonomy of the genus *Acinetobacter* with the recognition of *Acinetobacter baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter johnsonii* sp. nov., and *Acinetobacter junii* sp. nov. and emended descriptions of *Acinetobacter calcoaceticus* and *Acinetobacter lwoffii*. *Int J Syst Bacteriol.* 36:228 – 240.
4. Bouvet, P. J. M., and P. A. D. Grimont. 1987. Identification and biotyping of clinical isolates of *Acinetobacter*. *Ann Inst Pasteur Microbiol.* 138: 569 – 578.
5. Bouvet, P. J. M., and S. Jeanjean. 1989. Delineation of new proteolytic genospecies in the genus *Acinetobacter*. *Res Microbiol.* 140:291 – 299.
6. Bergogne-Berezin, E., and K.J. Towner. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev.* 9:148-165.
7. Bergogne-Berezin, E., and K.J. Towner. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev.* 9:148-165.
8. Bonomo, R.A., and D. Szabo. 2006. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis.* 43 Suppl 2:S49-56.
9. Corvec, S. 2003. AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J Antimicrob Chemother.* 52:629-635.
10. Corvec, S., L. Poirel, T. Naas, H. Drugeon, and P. Nordmann. 2007. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 51:1530-1533.
11. Chen, T.L., R.C.C. Wu, M.F. Shaio, C.P. Fung, and W.L. Cho. 2008. Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 52:2573-2580.
12. Chiu, C.H., H.Y. Lee, L.Y. Tseng, C.L. Chen, J.H. Chia, L.H. Su, and S.Y. Liu. 2010. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in *Acinetobacter baumannii* clinical isolates in Taiwan. *Int J Antimicrob Agents.* 35:382-386.
13. Damier-Piolle, L., S. Magnet, S. Bremont, T. Lambert, and P. Courvalin. 2007. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 52:557-562.
14. Dent, L.L., D.R. Marshall, S. Pratap, and R.B. Hulet. 2010. Multidrug resistant *Acinetobacter baumannii*: a descriptive study in a city hospital. *BMC Infect Dis.* 10:196.
15. Di Popolo, A., M. Giannouli, M. Triassi, S. Brisse, and R. Zarrilli. 2011. Molecular epidemiological investigation of multidrug-resistant *Acinetobacter baumannii* strains in four Mediterranean countries with a multilocus sequence typing scheme. *Clin Microbiol Infect.* 17:197-201.
16. Fischbach, M.A., and C.T. Walsh. 2009. Antibiotics for emerging pathogens. *Science.* 325:1089-1093.
17. Fishbain, J., and Anton Y. Peleg. 2010. Treatment of *Acinetobacter* Infections. *Clin Infect Dis.* 51:79-84.
18. Fu, Y., J. Zhou, H. Zhou, Q. Yang, Z. Wei, Y. Yu, and L. Li. 2010. Wide dissemination of OXA-23-producing carbapenem-resistant *Acinetobacter baumannii* clonal complex 22 in multiple cities of China. *J Antimicrob Chemother.* 65:644-650.
19. Gordon, N.C., and D.W. Wareham. 2010. Multidrug-resistant *Acinetobacter baumannii*: mechanisms of virulence and resistance. *Int J Antimicrob Agents.* 35:219-226.
20. Hujer, K. M., N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2005. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. *Antimicrob Agents Chemother.* 49:2941-2948.
21. Heritier, C., L. Poirel, and P. Nordmann. 2006. Cephalosporinase over-expression resulting from insertion of ISAbal in *Acinetobacter baumannii*. *Clin Microbiol Infect.* 12:123-130.
22. Hu, W.S., S.M. Yao, C.P. Fung, Y.P. Hsieh, C.P. Liu, and J.F. Lin. 2007. An OXA-66/OXA-51-Like Carbapenemase and possibly an efflux pump are associated with resistance to imipenem in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 51:3844-3852.
23. He, C., Y. Xie, L. Zhang, M. Kang, C. Tao, Z. Chen, X. Lu, L. Guo, Y. Xiao, L. Duo, and H. Fan. 2010. Increasing imipenem resistance and dissemination of the ISAbal-associated blaOXA-23 gene among *Acinetobacter baumannii* isolates in an intensive care unit. *J Med Microbiol.* 60:337-341.
24. Jain, R. 2004. Multidrug-resistant *Acinetobacter* infections: an emerging challenge to clinicians. *Ann Pharmacother.* 38:1449-1459.
25. Koort, J.M.K., S. Lukinmaa, M. Rantala, E. Unkila, and A. Siitonen. 2002. Technical improvement to prevent DNA degradation of enteric pathogens in pulsed-field gel electrophoresis. *J Clin Microbiol.* 40:3497-3498.
26. Kim, S., Y. J. Park, S. H. Kim, J. C. Lee, Y. C. Lee, S. Y. Seol, D. T. Cho, J. Kim. 2011. Novel cut-circular ligation-PCR (CCL-PCR) method for subtyping of *Acinetobacter baumannii* carrying ISAbal. ISSAR 2011. April 6-8, 2011 COEX, Seoul, Korea.
27. Lee, K., J.H. Yum, D. Yong, H.M. Lee, H.D. Kim, J.D. Docquier, G.M. Rossolini, and Y. Chong. 2005. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother.* 49:4485-4491.
28. Liu, Y. G., and Y. Chen. 2007. High-efficiency thermal asymmetric interlaced PCR for amplification of unknown flanking sequences. *BioTechniques.*

43:649-656. 29.Lee, Y.T., L.Y. Huang, D.H. Chiang, C.P. Chen, T.L. Chen, F.D. Wang, C.P. Fung, L.K. Siu, and W.L. Cho. 2009. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible *Acinetobacter* isolates belonging to different genomic species in Taiwan. *Int J Antimicrob Agents*. 34:580-584. 30.Lee, Y., C.K. Kim, H. Lee, S.H. Jeong, D. Yong, and K. Lee. 2010. A novel insertion sequence, ISAb10, inserted into ISAb1 adjacent to the blaOXA-23 gene and disrupting the outer membrane protein gene carO in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 55:361-363. 31.Lee, H. Y., C. L. Chen, S. B. Wang, L. H. Su, S. H. Chen, S. Y. Liu, T. L. Wu, T. Y. Lin, and C. H. Chiu. 2011. Imipenem heteroresistance induced by imipenem in multidrug-resistant *Acinetobacter baumannii*: mechanism and clinical implications. *Int J Antimicrob Agents*. 37:302-308. 32.Magnet, S., P. Courvalin, and T. Lambert. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother*. 45:3375-3380. 33.Mammeri, H., L. Poirel, N. Mangeney, and P. Nordmann. 2003. Chromosomal integration of a cephalosporinase gene from *Acinetobacter baumannii* into *oligella urethralis* as a source of acquired resistance to -lactams. *Antimicrob Agents Chemother*. 47:1536-1542. 34.Mugnier, P.D., L. Poirel, T. Naas, and P. Nordmann. 2010. Worldwide dissemination of the blaOXA-23 carbapenemase gene of *Acinetobacter baumannii*. *Emerg Infect Dis*. 16:35-40. 35.Poirel, L., E. Lebessi, C. Heritier, A. Patsoura, M. Foustoukou, and P. Nordmann. 2006. Nosocomial spread of OXA-58-positive carbapenem-resistant *Acinetobacter baumannii* isolates in a paediatric hospital in Greece. *Clin Microbiol Infect*. 12:1138-1141. 36.Segal, H., R.K. Jacobson, S. Garny, C.M. Bamford, and B.G. Elisha. 2007. Extended 10 promoter in ISAb-1 upstream of blaOXA-23 from *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 51:3040-3041. 37.Tenover, F.C., R.D. Arbeit, R.V. Goering, P.A. Mickelsen, B.E. Murray, D.H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol*. 33:2233-2239. 38.Wilson, L.A. 2006. Enterobacterial repetitive intergenic consensus (ERIC) sequences in *Escherichia coli*: evolution and implications for ERIC-PCR. *Mol Biol Evol*. 23:1156-1168. 39.Wang, X., Z. Zong, and X. Lu. 2011. Tn2008 is a major vehicle carrying blaOXA-23 in *Acinetobacter baumannii* from China. *Diagn Microbiol Infect Dis*. 69:218-222. 40.Yang, J. L. 2008. A simple and rapid method for extracting bacterial DNA from intestinal microflora for ERIC-PCR detection. *World J Gastroenterol*. 14:2872. 41.Zhang, J.P., W. Zhu, Y.Z. Chu, S.F. Tian, and B.Y. Chen. 2010. Molecular epidemiological study of multi-drug resistant *Acinetobacter baumannii*. *Zhonghua Nei Ke Za Zhi*. 49:657-661.